Research

Crohn's Disease trial funding success: cine MRI

Joint collaborations between members of the British Society of Gastrointestinal and Abdominal Radiology (BSGAR) and the BSG have led to recent grant success from the NIHR. Led by Prof Stuart Taylor and Dr Andrew Plumb, the team has been awarded £895,292 by NIHR EME to investigate “Small bowel motility quantified by cine MRI as a predictor of long term response in patients with Crohn's disease commencing biological therapy”. The trial will recruit from 10 centers and perform dynamic cine MRI imaging of the small bowel in those commencing biological therapies for active disease. Small bowel motility is reduced by active inflammation and this can be quantified using MRI and specialist analysis software. The study will test if early improvement in small bowel motility after commencing therapy is better predictive of 1 year response or remission than CRP or calprotectin. An embedded mechanistic study led by Dr Gordon Moran will explore the relationship between gut peptides, inflammatory cytokines, aberrant small bowel motility on MRI, and patient abdominal symptoms. A team led by Prof Ailsa Hart will investigate the effect of body composition on patient response. Co-investigators: Gordon Moran, Ailsa Hart, Alex Menys, Andrew Plumb, Stuart Bloom, Tariq Ahmad, Ilan Jacobs, Susan Tebbs, Caroline Dore, Simon Travis, Steve Halligan.

NIHR Study Support Service Route Map

Planning to deliver a study in the NHS? Take a look at the route map to see when and how support can be offered by the NIHR Study Support Service.

TRITON grant announcement

Professor Spiller and a team of experts from the Neurogastroenterology & Motility Section of the British Society of Gastroenterology who are based in 12 major research centres in the UK have been awarded a £2.1M grant from the National Institute of Health Research Efficacy and Mechanism Evaluation (NIHR EME) Programme to perform a clinical trial entitled "Treatment of IBS with diarrhoea with Titrated Ondansetron (TRITON)”. The trial will be coordinated from the Leeds Clinical Trials Research Unit and the mechanistic studies will involve specialist centres in Leeds, University College London and Barts and the London Hospital. Recruitment is expected to start in autumn 2017.

The trial offers a great opportunity for two specialist registrars to obtain a higher degree in the rapidly expanding field of neurogastroenterology. The trial will include studies of how ondansetron affects bowel motility and sensitivity. Understanding how ondansetron works will improve our ability to predict who will respond and will inform the development of new treatments for this common and distressing condition. One registrar will be based at QMC, Nottingham and the other at QMUL, London; both are expected to start their fully supported OOP work in September 2017. The posts will be advertised soon with full information on how to apply.

New HRA approval leaflet

The Health Research Authority (HRA) has published a new brief leaflet setting out high level information about the HRA Approval process. It provides an overview, highlighting their aim to simplify and streamline the approval process. Detailed guidance is also available from the HRA website. For help or to share feedback, This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

New Wilson Disease trial recruiting now

8 Feb 2016

A phase 2, multi-centre, international therapeutic trial has been approved in the UK for patients with Wilson's disease. The Royal Surrey County Hospital, Guildford and Queen Elizabeth Hospital, Birmingham are the two UK sites, both of which have begun recruiting. Please refer to the letter to physicians for more detail and to get involved.

Page 2 of 3